Oppenheim; Joost J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Oppenheim; Joost J..The latest application filed is for "human monoclonal antibody targeting tnfr2 for cancer immunotherapy".

Company Profile

2.7.15

Oppenheim; Joost J. - Bethesda MD
Oppenheim; Joost J. - Rockville MD
Oppenheim; Joost J. - Frederick MD
Oppenheim, Joost J. - Bethrsda MD
Oppenheim, Joost J - Bethesda MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy Grant 11,389,480 - Oppenheim , et al. July 19, 2	2022-07-19
Therapeutic antitumor combination of a TLR4 ligand with other treatments Grant 11,266,746 - Oppenheim , et al. March 8, 2	2022-03-08
Human Monoclonal Antibody Targeting Tnfr2 For Cancer Immunotherapy App 20200230173 - Oppenheim; Joost J. ; et al.	2020-07-23
Therapeutic Antitumor Combination Of A Tlr4 Ligand With Other Treatments App 20190151466 - Oppenheim; Joost J. ; et al.	2019-05-23
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants Grant 9,567,566 - Yang , et al. February 14, 2	2017-02-14
Hmgn Polypeptides As Immune Enhancers And Hmgn Antagonists As Immune Suppressants App 20160296620 - Yang; De ; et al.	2016-10-13
Hmgn Polypeptides As Immune Enhancers And Hmgn Antagonists As Immune Suppressants App 20120269839 - Yang; De ; et al.	2012-10-25
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants Grant 8,227,417 - Yang , et al. July 24, 2	2012-07-24
Hmgn Polypeptides As Immune Enhancers And Hmgn Antagonists As Immune Suppressants App 20100021488 - Yang; De ; et al.	2010-01-28
Compositions and methods for enhancing an immune response App 20060008808 - Yang; De ; et al.	2006-01-12
Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR) App 20060008891 - Wang; Ji Ming ; et al.	2006-01-12
Amyloid beta is a ligand for FPR class receptors App 20050130890 - Wang, Ji Ming ; et al.	2005-06-16
Utilization of FPRL1 as a functional receptor by serum amyloid A (SAA) App 20050085629 - Wang, Ji Ming ; et al.	2005-04-21
T20/DP178 is an activator of human phagocyte formyl peptide receptors Grant 6,830,893 - Wang , et al. December 14, 2	2004-12-14
Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection Grant 6,808,877 - Wang , et al. October 26, 2	2004-10-26
LL-37 is an immunostimulant App 20040013679 - Chertov, Oleg ; et al.	2004-01-22
Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity App 20030211105 - Murphy, William J ; et al.	2003-11-13
T20/DP178 and T21/DP107 are activators of human phagocyte formyl peptide receptors App 20030203841 - Wang, Ji Ming ; et al.	2003-10-30
Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection App 20030147883 - Wang, Ji-Ming ; et al.	2003-08-07
Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA) App 20030120037 - Wang, Ji Ming ; et al.	2003-06-26
LL-37 is an immunostimulant App 20020072495 - Chertov, Oleg ; et al.	2002-06-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.